All Stories

Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies.

May 8, 2025 - 23:17
 0
Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs
California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies.
Read More

Tags:

Previous Article

Takeda shoots down bispecifics bagged in Maverick buyout amid pipeline clearout

Next Article

Charles River launches strategic review and shakes up board amid regulatory unce...

Related Posts

Fierce Biotech Layoff Tracker 2025: Caribou cuts 32% of staff; Mural lays off 90%

Fierce Biotech Layoff Tracker 2025: Caribou cuts 32% of...

Apr 25, 2025  0

Boston Scientific plans to make ground despite $200M in tariff headwinds

Boston Scientific plans to make ground despite $200M in...

Apr 24, 2025  0

Fecal transplants alleviate pain in mice and small trial of patients with fibromyalgia

Fecal transplants alleviate pain in mice and small tria...

Apr 28, 2025  0